Drug Discovery World

SEPTEMBER 3, 2024

Life sciences researchers need a host of tools to develop and test critical disease-treating drugs and therapies, from basic research to final product release. The post Free event: Next generation predictive in vitro ADMET solutions appeared first on Drug Discovery World (DDW). Register for free now to secure your place.

Pharmacokinetics 130

Pharmacokinetics Production Science Pharmaceuticals 130

Drug Discovery World

DECEMBER 21, 2022

Biopharmaceutical company Rezolute has initiated a Phase II proof-of-concept study for RZ402, a plasma kallikrein inhibitor (PKI) being developed as an oral therapy for the treatment of diabetic macular oedema (DMO). . The post Oral therapy for diabetic macular oedema progresses to Phase II appeared first on Drug Discovery World (DDW).

Therapies 130

Therapies Pharmacokinetics Clinical Development Treatment 130

Drug Discovery World

AUGUST 27, 2024

Life sciences researchers need a host of tools to develop and test critical disease-treating drugs and therapies, from basic research to final product release. The post Webinar: Create advanced predictive models for tox testing appeared first on Drug Discovery World (DDW). Register for free now to secure your place.

Pharmacokinetics 130

Pharmacokinetics Production Science Pharmaceuticals 130

Drug Discovery World

AUGUST 20, 2024

Life sciences researchers need a host of tools to develop and test critical disease-treating drugs and therapies, from basic research to final product release. The post Webinar: Building advanced cell models for toxicity testing appeared first on Drug Discovery World (DDW). Register for free now to secure your place.

Pharmacokinetics 130

Pharmacokinetics Production Science Pharmaceuticals 130

Drug Discovery World

FEBRUARY 2, 2024

Sunday 4 February is World Cancer Day, an international awareness day led by the Union for International Cancer Control (UICC), so the round-up this week will focus on oncology, including the UK approval of a rare blood cancer drug and a novel production process for CAR-T therapies.

Pharmacokinetics 130

Pharmacokinetics Drugs International Clinical Trials 130

ASPET

JULY 15, 2024

XELOX therapy, which comprises capecitabine and oxaliplatin, is the standard first-line chemotherapeutic regimen for colorectal cancer. Mathematical modeling combining pharmacokinetics (PK) and toxicodynamics (TD) is a promising approach for optimizing dosing strategies and reducing toxicity.

Pharmacokinetics 40

Pharmacokinetics Therapies Drugs Treatment 40

Drug Discovery World

APRIL 3, 2024

The aim of the project is the preclinical and clinical development of the antifibrinolytic agent CM-352, a first-in-class drug that represents a pioneering therapeutic approach to control severe bleeding in unmet medical needs, such as those associated with major surgery, trauma or intracranial haemorrhage (ICH). .

Therapies 130

Therapies Laboratories Pharmacokinetics Treatment 130

ASPET

JUNE 10, 2024

Radiation therapy, a standard treatment option for many cancer patients, induces DNA double strand breaks (DSBs), leading to cell death. Efficacy of radiosensitizers for brain tumors may be influenced by a lack of effective drug delivery across the blood-brain barrier (BBB).

Pharmacokinetics 40

Pharmacokinetics Pharmacogenetics Treatment DNA 40

Drug Discovery World

OCTOBER 30, 2023

FIT-001 is a first-in-human, multicentre, open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of KO-2806 when administered as monotherapy and in combination with targeted therapies.

Trials 130

Trials Pharmacokinetics Therapies Treatment 130

Drug Discovery World

MARCH 15, 2024

Biotechnology company Allyx Therapeutics has reported positive Phase Ib clinical data for its lead compound, ALX-001, a first-in-class, synapse-targeted, disease-modifying oral therapy in development for neurodegenerative diseases. The findings were presented at the AD/PD 2024 Conference in Lisbon.

Disease 130

Disease Trials Small Molecule Pharmacokinetics 130

Drug Discovery World

SEPTEMBER 6, 2022

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Avacta Group’s chemotherapy drug, AVA6000, for the treatment of soft tissue sarcoma. . This designation qualifies the developer of the drug for certain incentives, like seven years of market exclusivity upon drug approval from the FDA.

FDA 130

FDA Pharmacokinetics Drugs Clinical Trials 130

Drug Discovery World

DECEMBER 22, 2023

Positive Phase I results for a new solid dose prescription cannabidiol (CBD) demonstrate the tolerability and bioavailability of the drug. Neuroscience drug discovery company Sapient Therapeutics successfully completed Part B of the Phase I trial comparing its CBD therapy SAP021 with Epidiolex.

Pharmacokinetics 130

Pharmacokinetics Clinical Development FDA Trials 130

Drug Discovery World

JUNE 27, 2023

Together, the three institutions, in collaboration with Therapeutic Innovation Australia (TIA), will guide early-stage projects through the process of identifying drug candidates with potential commercial value. MedChem Australia will fill this gap.

Drugs 130

Drugs Medical Chemistry Pharmacokinetics Science 130

Drug Discovery World

MARCH 10, 2023

“Enfortumab vedotin has become a second- and third-line treatment option for many patients around the world with previously treated locally advanced or metastatic urothelial cancer, and an approval in China may bring this therapy to those patients.” The five-year prevalence of bladder cancer in China is estimated to be 16.26/100,000

Pharmacokinetics 130

Pharmacokinetics Drugs Licensing Licensing 130

Drug Discovery World

FEBRUARY 27, 2024

The Phase I clinical trial of ARV-102 will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARV-102, including the evaluation of LRRK2 degradation and exploratory LRRK2 pathway biomarkers. The post First PROTAC degrader for neurodegenerative disease enters trials appeared first on Drug Discovery World (DDW).

Trials 130

Trials Disease Clinical Trials Pharmacokinetics 130

Drug Discovery World

JANUARY 31, 2024

Breye Therapeutics, a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, has started a Phase Ib/IIa clinical trial to investigate danegaptide, following oral administration, in patients suffering from diabetic macular oedema (DMO).

Treatment 130

Treatment Clinical Trials Pharmacokinetics Trials 130

Drug Discovery World

JANUARY 10, 2024

Early studies of AIO-001 have shown initial safety, tolerability, pharmacokinetics, and biological activity in healthy volunteers and asthma patients. The post GSK expands respiratory pipeline with Aiolos Bio acquisition appeared first on Drug Discovery World (DDW).

Pharmacokinetics 130

Pharmacokinetics Licensing Licensing Clinical Development 130

Drug Discovery World

JUNE 29, 2023

DDW’s Diana Spencer provides an overview of the latest innovations in drug discovery for mental health. To mark the occasion, this article summarises the most recent news about the ways drug discovery is improving wellbeing and mental health through innovative new treatments and therapies.

Drugs 130

Drugs Pharmacokinetics Trials FDA 130

Drug Discovery World

DECEMBER 12, 2023

Exonate, an mRNA therapy company focused on treatments for diabetic complications, has announced that its lead ophthalmology asset, EXN407, has achieved its prespecified endpoints in a Phase Ib/IIa study. During the trial, EXN407 met all safety and pharmacokinetic parameters and displayed encouraging signals of biological activity.

Small Molecule 130

Small Molecule Trials Pharmacokinetics Treatment 130

Drug Discovery World

JUNE 27, 2023

By starting with the body’s response to disease, as opposed to the target itself, Alchemab’s platform inverts the traditional ‘target-led’ drug discovery process. This could lead to a potent drug with fewer side effects.

Pharmacokinetics 130

Pharmacokinetics Therapies Disease Treatment 130

Drug Discovery World

SEPTEMBER 26, 2022

DDW Editor Reece Armstrong explores the rise of drug repurposing and the benefits and disadvantages it brings to drug discovery and development. . Drug repurposing, the act of finding new clinical targets for both approved and unapproved drugs, has emerged as a viable alternative to traditional drug discovery approaches. .

Pharmaceutical Companies 130

Pharmaceutical Companies Drugs Pharmaceuticals Clinical Trials 130

Drug Discovery World

OCTOBER 13, 2022

The DDW team spent 4-5 October, 2022 at ELRIG’s annual meeting, Drug Discovery 2022, which remains Europe’s largest meeting for life sciences industry professionals and took place at ExCel, London, UK. Drug Discovery 2022: The numbers . Drug Discovery 2022: The numbers . Of those delegates, 75% work in drug discovery.

Drugs 130

Drugs Cell Based Assays Science Assay Development 130

Drug Discovery World

NOVEMBER 20, 2023

Biologics represents the fastest-growing sector of the pharmaceutical industry, with hundreds of therapies approved in recent years 3,4. mRNA vaccines and antibody therapies in particular are promising areas that are already having significant impact across the healthcare industry, with enormous potential to address unmet medical needs.

DNA 173

DNA Engineering Vaccine Therapies 173

The Pharma Data

JULY 2, 2023

The new approach in cancer therapy with innovative mechanism-of-action for ferroptosis induction A team of researchers led by Dr. Marcus Conrad from Helmholtz Munich discovered a novel anti-cancer drug, called icFSP1, which sensitizes cancer cells to ferroptosis.

Therapies 40

Therapies Small Molecule Pharmacokinetics Disease 40

Drug Discovery World

NOVEMBER 29, 2022

The new Clinical Pharmacology degree was launched in 2019 by Professors Emma Baker and Iain Greenwood and aims to take a holistic view of the development of drugs and create graduates that will stand out in the job market. Starting with the drug. Pharmacokinetics: How the body handles drugs.

Clinical Pharmacology 130

Clinical Pharmacology Clinical Trials Drugs Drug Development 130

ASPET

SEPTEMBER 28, 2023

These protocols were then used to determine the plasma pharmacokinetics of agmatine and the extent of distribution to the CNS. Precision and accuracy of the protocol met Food and Drug Administration (FDA) standards in surrogate matrix, as well as in corrected concentrations in appropriate matrices.

Pharmacokinetics 40

Pharmacokinetics FDA Therapies Drugs 40

Alta Sciences

OCTOBER 30, 2023

TOP NONCLINICAL SCIENTIFIC RESOURCES eBook : Safety Assessment for Ophthalmic Products Designing preclinical studies for ocular therapies take a lot of deliberation. The Altascientist : Issue No. Read or listen now. Read the blog. TOP MANUFACTURING AND ANALYTICAL RESOURCES The Altascientist : Issue No.

Science 52

Science Clinical Trials Pharmacokinetics Pharmacy 52

DrugBank

MARCH 7, 2024

The landscape of weight loss drugs has been rapidly evolving, and 2024 is poised to be another transformative year in this market. As we step into 2024, the momentum is expected to continue, with analysts projecting the weight loss drug market to reach remarkable heights, potentially hitting $100 billion by the end of the decade.

Pharmaceutical Companies 82

Pharmaceutical Companies Pharmaceuticals Clinical Trials Pharmacokinetics 82

Drug Target Review

DECEMBER 12, 2023

We use hydrophilic linkers, which prevent ADC aggregation and generate highly stable ADCs, in combination with a unique attachment site on the antibody to create ADCs that retain pharmacokinetic properties similar to the original unconjugated antibody. This helps to maximize the targeted payload delivery to tumor cells.

Treatment 114

Treatment Engineering Pharmacokinetics Doctors 114

The Pharma Data

OCTOBER 15, 2020

Vertex Pharmaceuticals has decided to give up on its experimental VX-814, a small molecule drug for the rare genetic disease Alpha-1 antitrypsin deficiency (AATD), canning the drug’s development after seeing lackluster results from an early phase 2 trial. James Miessler.

Disease 52

Disease Small Molecule Pharmacokinetics Licensing 52

PPD

OCTOBER 12, 2023

Cell and gene therapies (CGTs) are one of the fastest growing areas in human therapeutics. Since chimeric antigen receptor T cell (CAR-T) therapy was first approved in 2017, there has been a marked increase of cell and gene therapy studies resulting in significant changes in the way diseases are treated as well as patient outcomes.

Laboratories 52

Laboratories Protein Expression Clinical Trials Pharmacokinetics 52

Drug Discovery World

AUGUST 10, 2022

But decades of research led to improvements in cancer therapy, centred around the idea that one’s immune system could aid in treatment. Next, the advent of antibody treatments in 1997 created the first targeted cancer therapy 2. Since 2017, five CAR T cell therapies have been approved and have shown incredible success in the clinic.

Therapies 246

Therapies Virus Treatment Engineering 246

Drug Discovery World

AUGUST 22, 2023

So, there is a huge potential for generics companies to take the lead in relieving this burden and driving sustainable access to advanced therapies, particularly for currently underserved patient populations. These advanced therapies are transforming the medical landscape and are emerging as the future of patient care.

Production 130

Production Pharma Companies Clinical Trials FDA 130

The Pharma Data

MARCH 25, 2021

With more than six years of patient experience, a positive benefit-risk profile, strong clinical data and robust real-world data, the totality of evidence solidifies the role of IBRANCE plus endocrine therapy as a treatment for patients with HR+, HER2- metastatic breast cancer.”. The analysis also showed the two-year OS rate was 78.3%

Therapies 52

Therapies Clinical Trials Trials Treatment 52

Drug Target Review

JUNE 12, 2023

TEAD proteins are crucial for tumour progression and drug resistance, making them an attractive focus for therapeutic interventions. Leveraging AI-guided structure-based drug design, Insilico’s research and development team generated an impressive portfolio of over 6,000 molecules and identified three highly promising hit series.

Metabolic Stability 92

Metabolic Stability Clinical Trials Small Molecule Pharmacokinetics 92

The ChEMBL-og

APRIL 16, 2024

We are delighted to announce the release of ChEMBL 34, which includes a full update to drug and clinical candidate drug data. 71 out of the 882 newly added EMA drugs are only authorised by EMA, rather than from other regulatory bodies e.g. FDA. This data is currently available for European Medicines Agency drugs only.

Clinical Trials 108

Clinical Trials FDA Cell Based Assays Packaging 108

The Pharma Data

MARCH 9, 2022

Sanofi and Swedish Orphan Biovitrum AB (publ) (Sobi ® ) (STO:SOBI) today announced positive topline results from the pivotal XTEND-1 Phase 3 study evaluating the safety, efficacy and pharmacokinetics of efanesoctocog alfa (BIVV001) in previously treated patients ? 12 years of age with severe hemophilia A.

Treatment 52

Treatment Pharmacokinetics Therapies FDA 52